Company / Interest Expense
Coherus Oncology, Inc. Interest Expense History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$17.6M
FY2019
5-year range
$3.9M / $17.6M
FY2015-FY2019
Trend
+81.8%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Interest Expense has increased for 3 consecutive years, from $4M in FY2016 to $18M in FY2019.
Based on SEC 10-K filings.
$18M in FY2019 with a 5-year CAGR of +63.3%.
Increased from $10M to $18M over the past 2 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- +65.3%
- 5-Year CAGR
- +63.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- Coherus Oncology, Inc.'s interest expense has grown for 3 consecutive years.
- 5-year CAGR of +63.3%, indicating consistent growth.
- In FY2019, interest expense increased 81.8% year-over-year.
- Lowest interest expense in the period was in FY2014.
Company context
Key Data Points
- Altman Z-Score -0.49 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $17.6M | +81.8% |
| FY2018 | $9.7M | +1.4% |
| FY2017 | $9.6M | +144.9% |
| FY2016 | $3.9M | -26.3% |
| FY2015 | $5.3M | +249.6% |
| FY2014 | $1.5M | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026